Insmed was one of the 5 biotechnology stocks recommended to buy now .This is a strong week for Insmed Incorporated Insmed. The company’s rating climbs to B from the previous week’s C. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Investors seem to agree with the upgraded status of the stock and have pushed the stock up 5.4% over the past month.
investor place has it all there from December 25th
Best regards to everyone